Company
Karyopharm Therapeutics
Karyopharm Therapeutics has 9 drugs tracked on RxWires: 1 in Phase 3, 2 in Phase 2, 2 in Phase 1/2, 4 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| Selinexor | Phase 3 | Myelofibrosis |
| Elotuzumab, Selinexor, and Dexamethasone (ESd) | Phase 2 | Relapsed Multiple Myeloma |
| Open Label Selinexor | Phase 2 | Thymoma |
| KPT-8602 | Phase 1/2 | Relapsed/Refractory Multiple Myeloma (RRMM) |
| Pembrolizumab | Phase 1/2 | Advanced Urothelial Carcinoma |
| KPT-330 | Phase 1 | Diffuse Large B-Cell Lymphoma |
| KCP-330 | Phase 1 | Sarcoma |
| Verdinexor | Phase 1 | Healthy |
| Eltanexor | Phase 1 | Relapsed Myelodysplastic Syndrome |
Latest
- Licensing / Collaboration Deal: karyopharm therapeutics
- Merger or Acquisition: karyopharm therapeutics
- karyopharm therapeutics filed 8-K
- karyopharm therapeutics filed 8-K
- karyopharm therapeutics filed 8-K
Follow Karyopharm Therapeutics on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.